Literature DB >> 2786779

Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis.

J A Snook1, R W Chapman, K Fleming, D P Jewell.   

Abstract

We have previously described circulating autoantibodies to a portal tract antigen in patients with primary sclerosing cholangitis. In this study the antigen has been shown by double-labelling studies to be specifically located in the nuclei of tissue neutrophils. Using isolated peripheral blood neutrophils and an immunoperoxidase technique, anti-neutrophil nuclear antibody (ANNA) was found in the serum of 84% of patients with primary sclerosing cholangitis (PSC: n = 32) with a median titre of 1/1000 and a peak titre of 1/500,000. ANNA was also detected in 86% of patients with inflammatory bowel disease alone (IBD: n = 76) with a median titre of 1/10 and a peak titre of 1/10,000. In contrast, only 12% of controls had ANNA, and in none was the titre greater than 1/10. In PSC the ANNA titre correlated with the serum aspartate transaminase concentration, suggesting that it is related to disease activity. In IBD the titre of ANNA was significantly higher in patients with recently active disease. There was no significant difference between the titres seen in ulcerative colitis and Crohn's disease. ANNA was not associated with neutropaenia. The results provide further evidence of involvement of autoimmune mechanisms in inflammatory bowel disease and primary sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786779      PMCID: PMC1541734     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Protein abnormalities in ulcerative colitis patients and their families.

Authors:  W R THAYER; H M SPIRO
Journal:  Gastroenterology       Date:  1963-04       Impact factor: 22.682

2.  Fluorescent antiglobulin studies in leukopenic and related disorders.

Authors:  P CALABRESI; E A EDWARDS; R F SCHILLING
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

3.  DEMONSTRATION OF CIRCULATING ANTINUCLEAR GLOBULINS IN ULCERATIVE COLITIS.

Authors:  P Calabresi; W R Thayer; H M Spiro
Journal:  J Clin Invest       Date:  1961-12       Impact factor: 14.808

4.  Antinuclear factors and human leucocytes: reaction with granulocytes and lymphocytes.

Authors:  M J Smalley; I R Mackay; S Whittingham
Journal:  Australas Ann Med       Date:  1968-02

5.  Leucocyte-specific anti-nuclear factors in patients with felty's syndrome, rheumatoid arthritis, systemic lupus erythematosus and other diseases.

Authors:  V Faber; P Elling
Journal:  Acta Med Scand       Date:  1966-03

6.  Antinuclear antibodies in ankylosing spondylitis, psoriatic arthritis, and psoriasis.

Authors:  J N Rosenberg; G D Johnson; E J Holborow
Journal:  Ann Rheum Dis       Date:  1979-12       Impact factor: 19.103

7.  An autoantibody reactive with nuclei of polymorphonuclear neutrophils: a cell differentiation marker.

Authors:  S Whittingham; G Morstyn; J W Wilson; M A Vadas
Journal:  Blood       Date:  1981-10       Impact factor: 22.113

8.  Association of primary sclerosing cholangitis with HLA-B8.

Authors:  R W Chapman; Z Varghese; R Gaul; G Patel; N Kokinon; S Sherlock
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

9.  Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis.

Authors:  R W Chapman; M Cottone; W S Selby; H A Shepherd; S Sherlock; D P Jewell
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

10.  Lactoferrin: nuclear localization in the human neutrophilic granulocyte?

Authors:  R C Briggs; W F Glass; M M Montiel; L S Hnilica
Journal:  J Histochem Cytochem       Date:  1981-10       Impact factor: 2.479

View more
  32 in total

Review 1.  Churg-Strauss syndrome.

Authors:  M Conron; H L Beynon
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Are the inflammatory bowel diseases autoimmune disorders?

Authors:  J Snook
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

3.  [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].

Authors:  A Schnabel; E Csernok; H Schultz; M Stoffel; C Herzberg; S F Carroll; W L Gross
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 4.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

5.  Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.

Authors:  F Seibold; P Weber; R Klein; P A Berg; K H Wiedmann
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

Review 6.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 7.  Antineutrophil cytoplasmic antibody--a useful serological marker for vasculitis.

Authors:  J A Goeken
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

Review 8.  Neutrophil autoantibodies as disease markers for ulcerative colitis.

Authors:  F Shanahan; C Landers; R Duerr; S R Targan
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 9.  Aetiology and natural history of primary sclerosing cholangitis--a decade of progress?

Authors:  R W Chapman
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

10.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

Authors:  J A Savige; B Paspaliaris; R Silvestrini; D Davies; T Nikoloutsopoulos; A Sturgess; J Neil; W Pollock; K Dunster; M Hendle
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.